Future of Personalized Medicine in Non-Small-Cell Lung Cancer
Excerpt
The remarkable progress we are witnessing in the understanding of the molecular biology and signalling pathways of non-small-cell lung cancer (NSCLC) cells has resulted in ErbB-targeted therapies and many other targeted agents, especially Alk inhibitors, now in clinical trials [...]
Share and Cite
Hirsh, V. Future of Personalized Medicine in Non-Small-Cell Lung Cancer. Curr. Oncol. 2012, 19, 86. https://doi.org/10.3747/co.19.1049
Hirsh V. Future of Personalized Medicine in Non-Small-Cell Lung Cancer. Current Oncology. 2012; 19(s1):86. https://doi.org/10.3747/co.19.1049
Chicago/Turabian StyleHirsh, V. 2012. "Future of Personalized Medicine in Non-Small-Cell Lung Cancer" Current Oncology 19, no. s1: 86. https://doi.org/10.3747/co.19.1049
APA StyleHirsh, V. (2012). Future of Personalized Medicine in Non-Small-Cell Lung Cancer. Current Oncology, 19(s1), 86. https://doi.org/10.3747/co.19.1049